New cocktail aims to starve pancreatic tumors
NCT ID NCT05034627
First seen Oct 31, 2025 · Last updated Jun 22, 2026 · Updated 44 times
Summary
This early-phase trial tests a combination of two drugs, calaspargase pegol-mknl and cobimetinib, in 15 people with advanced or metastatic pancreatic cancer. The goal is to find the safest dose and see if the combo can shrink tumors by cutting off their nutrient supply. It is a small, first-in-human study focused on safety, not a proven treatment yet.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
calaspargase pegol-mknl and cobimetinib
What this could lead to
If it works, this could point toward a new treatment option for advanced pancreatic cancer by starving cancer cells of a key nutrient.
What could go wrong
This is a very early, small phase 1 trial with only 15 participants, so it may not lead to a proven treatment. There are also risks of serious side effects from the drug combination.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.